Plexxikon, a company focused on the discovery and development of novel small molecule pharmaceuticals to treat human disease, has selected Clinipace Worldwide, a digital CRO, to manage all aspects of four clinical trials comprising a phase I healthy volunteer study, a phase Ib rheumatoid arthritis (RA) study and two phase II oncology studies. 
  
“We chose Clinipace Worldwide to manage these important clinical trials based on Clinipace’s commitment to customer service,” said Paul Lin, MD, MBA, director of business development at Plexxikon. “Plexxikon’s programs are highly differentiated from its competition, and we needed a highly differentiated CRO to get the job done.”

“As a digital CRO, we know that successful trials hinge on the transparent exchange of trial and project data among all constituents,” said Jeff Williams, Clinipace CEO. “This platform enables our clients to substantially improve their ability to avoid problems and mitigate risk.”